APLS 2017 Annual Report

108 SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized . Apellis Pharmaceuticals, Inc. Date: March 19, 2018 By: /s/ Cedric Francois Cedric Francois President, Chief Executive Officer and Director Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated. Name Title Date /s/ Cedric Francois President, Chief Executive Officer and Director (Principal Executive Officer and Duly Authorized Officer) March 19, 2018 Cedric Francois /s/ Timothy E. Sullivan Chief Financial Officer and Treasurer (Principal Financial Officer and Duly Authorized Officer) March 19, 2018 Timothy E. Sullivan /s/ Nicole D. Perry Vice President, Finance (Principal Accounting Officer) March 19, 2018 Nicole D. Perry /s/ Gerald Chan Director March 19, 2018 Gerald Chan /s/ A. Sinclair Dunlop Director March 19, 2018 A. Sinclair Dunlop /s/ Alec Machiels Director March 19, 2018 Alec Machiels /s/ Stephanie M. O’Brien Director March 19, 2018 Stephanie M. O’Brien